NEW YORK (GenomeWeb News) – A Cepheid official said yesterday that the firm expects to receive Emergency Use Authorization from the US Food and Drug Administration soon for the firm's molecular test for the 2009 influenza A H1N1 virus.

Cepheid CFO Andrew Miller said yesterday at the UBS Global Life Sciences Conference held here that the firm expects to file for full FDA clearance of the test after it receives the EUA. He said that the test will identify H1, H3, and novel H1N1 strains and will provide results in 45 minutes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.

Oct
23
Sponsored by
PerkinElmer

This webinar will address a range of methods for optimizing small RNA library preparation.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.